Rumiko Okamoto

Bortezomib-Based Therapy for Newly Diagnosed Mantle-Cell Lymphoma

Tadeusz Robak, Huiqiang Huang, Jie Jin et al. · New England Journal of Medicine · 2015 · 385 citations · Full text

Medicine, Oncology, Pharmacotherapy +14

Monitoring of Hepatitis B Virus (HBV) DNA and Risk of HBV Reactivation in B-Cell Lymphoma: A Prospective Observational Study

Shigeru Kusumoto, Yasuhito Tanaka, Ritsuro Suzuki et al. · Clinical Infectious Diseases · 2015 · 149 citations · Full text

Medicine, Hematology, Oncology +15

Frontline bortezomib, rituximab, cyclophosphamide, doxorubicin, and prednisone (VR-CAP) versus rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) in transplantation-ineligible patients with newly diagnosed mantle cell lymphoma: final overall survival results of a randomised, open-label, phase 3 study

Tadeusz Robak, Jie Jin, Halyna Pylypenko et al. · The Lancet Oncology · 2018 · 140 citations

Medicine, Hematology, Oncology +15

Central nervous system event in patients with diffuse large B‐cell lymphoma in the rituximab era

Naoto Tomita, Masahiro Yokoyama, Wataru Yamamoto et al. · Cancer Science · 2011 · 88 citations

Medicine, Oncology, Cancer Immunology +9

Low-dose cisplatin and 5-fluorouracil in combination can repress increased gene expression of cellular resistance determinants to themselves.

Mitsuru Nishiyama, Wataru Yamamoto, J. S. Park et al. · PubMed · 1999 · 76 citations

Medicine, Oncology, Pharmacology +11